Revvity Signals Software Joins Anthropic Directory
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 01 2026
0mins
Revvity announced that its Revvity Signals Software business has joined Anthropic's directory for Model Context Protocol connectors, enabling scientists to access Signals AI capabilities and connected R&D knowledge through Claude. Through the Signals MCP connector, Claude can securely access information through Signals' intelligence layer, helping researchers search, understand and act on complex R&D data using natural language. "Signals AI was designed to help scientists transform connected R&D data into understanding, decisions and action," said Kevin Willoe, president of Revvity Signals Software. "By joining Anthropic's MCP ecosystem, we're extending the reach of our Signals AI beyond our Signals One platform and enabling researchers to combine Claude's reasoning capabilities with the governed data, ontology-driven scientific context and trusted knowledge managed across the entire Revvity Signals offering."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RVTY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RVTY
Wall Street analysts forecast RVTY stock price to rise
10 Analyst Rating
6 Buy
4 Hold
0 Sell
Moderate Buy
Current: 112.050
Low
105.00
Averages
113.38
High
123.00
Current: 112.050
Low
105.00
Averages
113.38
High
123.00
About RVTY
Revvity, Inc. provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. It has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards life sciences customers. The segment offers instruments, reagents, software, subscriptions, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the areas of reproductive health and emerging market diagnostics. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Revvity to Release Q2 2026 Financial Results
- Earnings Release Schedule: Revvity will announce its Q2 2026 financial results before market open on August 4, 2026, providing investors with insights into its latest financial performance and market trends.
- Conference Call Details: On the same day at 7:30 a.m. ET, CEO Prahlad Singh and CFO Max Krakowiak will host a conference call to discuss the financial results in depth and address investor questions.
- Company Background: Revvity focuses on health science solutions, achieving $2.9 billion in revenue for 2025 with approximately 11,000 employees, serving multiple sectors including pharmaceuticals and diagnostics, showcasing significant market influence.
- Global Customer Base: As part of the S&P 500 index, Revvity has customers in over 160 countries, reflecting its extensive impact and market penetration in the global health technology sector.
See More
Reasons to Avoid Investing in Revvity
- Organic Growth Weakness: Revvity's organic revenue growth averaged only 2.9% annually over the past two years, lagging behind the sector, indicating waning demand in its core business and the need for product and market strategy improvements to remain competitive.
- Declining Adjusted Operating Margin: The company's adjusted operating margin has decreased by 6 percentage points over the last five years, currently standing at 27%, which raises concerns among shareholders about future profitability improvements to enhance investment appeal.
- Falling EPS: Revvity's earnings per share (EPS) has declined by 14.7% annually over the past five years, suggesting that while revenue may have increased, the company's fixed cost structure has hindered its ability to adapt to decreasing demand, negatively impacting profitability.
- Overpriced Market Valuation: With a forward P/E ratio of 20.3 and a stock price of $112.79, Revvity's shares appear to be priced for significant positive expectations, leading analysts to recommend that investors consider other stocks with better potential.
See More
Market Capitalization Comparison: Revvity vs Clorox
- Market Cap Comparison: Revvity Inc (Ticker: RVTY) has a market capitalization of $11.78 billion compared to Clorox Co (Ticker: CLX) at $11.53 billion, indicating Revvity's relative strength in the market, which may attract more investor interest.
- Investor Misconceptions: Many novice investors mistakenly compare company values solely based on stock prices; however, market capitalization provides a more accurate assessment of a company's value, aiding investors in making informed decisions.
- Market Positioning Impact: Market capitalization not only affects a company's ranking among peers but also determines which mutual funds and ETFs are willing to hold the stock, particularly as large funds tend to focus on companies valued over $10 billion.
- Stock Performance: At Thursday's close, Revvity's stock rose approximately 7.6%, while Clorox fell about 0.2%, reflecting positive market sentiment and increased investor confidence in Revvity.
See More
U.S. Stocks Close Higher, Led by Tech Gains
- Tech Stock Surge: Intel's stock soared over 12% after Apple held exploratory talks with Intel and Samsung Electronics for U.S. processor production, indicating strong market confidence in tech stocks and driving gains across chipmakers.
- Oil Price Decline: WTI crude oil prices fell more than 3% as the ceasefire in the Middle East eased geopolitical risks, providing support for the stock market and reflecting market demand for stability amid fluctuating oil prices.
- New Home Sales Growth: U.S. March new home sales rose 7.4% month-over-month to 682,000, surpassing expectations of 652,000, indicating a robust recovery in the housing market that could bolster economic confidence.
- Positive Earnings Outlook: As of Tuesday, 83% of the 354 S&P 500 companies that reported Q1 earnings exceeded estimates, with projected earnings growth of 12% year-over-year, demonstrating sustained corporate profitability that may further drive stock market gains.
See More
US Stocks Rise, Nasdaq Hits All-Time High
- Nasdaq Milestone: The Nasdaq 100 index surged by 1.20%, reaching an all-time high, driven by robust performance in technology stocks, reflecting increased investor confidence in the tech sector's growth potential.
- Intel's Strong Surge: Intel's stock rose over 13%, leading chipmakers after Apple indicated exploratory discussions with Intel and Samsung to produce key processors in the US, which is expected to enhance Intel's market share and profitability.
- Economic Data Impact: March new home sales in the US rose by 7.4% month-over-month to 682,000 units, surpassing expectations and indicating signs of recovery in the housing market, while the April ISM services index fell slightly below expectations, highlighting the complexities of economic recovery that may influence future monetary policy.
- Crude Oil Price Drop: WTI crude oil prices fell by more than 4% as calm returned to the Middle East, easing geopolitical risks, which is expected to positively impact inflation expectations and provide support for the stock market.
See More
Revvity (RVTY) Q1 2026 Earnings Transcript
See More
Revvity to Release Q2 2026 Financial Results
- Earnings Release Schedule: Revvity will announce its Q2 2026 financial results before market open on August 4, 2026, providing investors with insights into its latest financial performance and market trends.
- Conference Call Details: On the same day at 7:30 a.m. ET, CEO Prahlad Singh and CFO Max Krakowiak will host a conference call to discuss the financial results in depth and address investor questions.
- Company Background: Revvity focuses on health science solutions, achieving $2.9 billion in revenue for 2025 with approximately 11,000 employees, serving multiple sectors including pharmaceuticals and diagnostics, showcasing significant market influence.
- Global Customer Base: As part of the S&P 500 index, Revvity has customers in over 160 countries, reflecting its extensive impact and market penetration in the global health technology sector.
See More
Reasons to Avoid Investing in Revvity
- Organic Growth Weakness: Revvity's organic revenue growth averaged only 2.9% annually over the past two years, lagging behind the sector, indicating waning demand in its core business and the need for product and market strategy improvements to remain competitive.
- Declining Adjusted Operating Margin: The company's adjusted operating margin has decreased by 6 percentage points over the last five years, currently standing at 27%, which raises concerns among shareholders about future profitability improvements to enhance investment appeal.
- Falling EPS: Revvity's earnings per share (EPS) has declined by 14.7% annually over the past five years, suggesting that while revenue may have increased, the company's fixed cost structure has hindered its ability to adapt to decreasing demand, negatively impacting profitability.
- Overpriced Market Valuation: With a forward P/E ratio of 20.3 and a stock price of $112.79, Revvity's shares appear to be priced for significant positive expectations, leading analysts to recommend that investors consider other stocks with better potential.
See More
Market Capitalization Comparison: Revvity vs Clorox
- Market Cap Comparison: Revvity Inc (Ticker: RVTY) has a market capitalization of $11.78 billion compared to Clorox Co (Ticker: CLX) at $11.53 billion, indicating Revvity's relative strength in the market, which may attract more investor interest.
- Investor Misconceptions: Many novice investors mistakenly compare company values solely based on stock prices; however, market capitalization provides a more accurate assessment of a company's value, aiding investors in making informed decisions.
- Market Positioning Impact: Market capitalization not only affects a company's ranking among peers but also determines which mutual funds and ETFs are willing to hold the stock, particularly as large funds tend to focus on companies valued over $10 billion.
- Stock Performance: At Thursday's close, Revvity's stock rose approximately 7.6%, while Clorox fell about 0.2%, reflecting positive market sentiment and increased investor confidence in Revvity.
See More
U.S. Stocks Close Higher, Led by Tech Gains
- Tech Stock Surge: Intel's stock soared over 12% after Apple held exploratory talks with Intel and Samsung Electronics for U.S. processor production, indicating strong market confidence in tech stocks and driving gains across chipmakers.
- Oil Price Decline: WTI crude oil prices fell more than 3% as the ceasefire in the Middle East eased geopolitical risks, providing support for the stock market and reflecting market demand for stability amid fluctuating oil prices.
- New Home Sales Growth: U.S. March new home sales rose 7.4% month-over-month to 682,000, surpassing expectations of 652,000, indicating a robust recovery in the housing market that could bolster economic confidence.
- Positive Earnings Outlook: As of Tuesday, 83% of the 354 S&P 500 companies that reported Q1 earnings exceeded estimates, with projected earnings growth of 12% year-over-year, demonstrating sustained corporate profitability that may further drive stock market gains.
See More
US Stocks Rise, Nasdaq Hits All-Time High
- Nasdaq Milestone: The Nasdaq 100 index surged by 1.20%, reaching an all-time high, driven by robust performance in technology stocks, reflecting increased investor confidence in the tech sector's growth potential.
- Intel's Strong Surge: Intel's stock rose over 13%, leading chipmakers after Apple indicated exploratory discussions with Intel and Samsung to produce key processors in the US, which is expected to enhance Intel's market share and profitability.
- Economic Data Impact: March new home sales in the US rose by 7.4% month-over-month to 682,000 units, surpassing expectations and indicating signs of recovery in the housing market, while the April ISM services index fell slightly below expectations, highlighting the complexities of economic recovery that may influence future monetary policy.
- Crude Oil Price Drop: WTI crude oil prices fell by more than 4% as calm returned to the Middle East, easing geopolitical risks, which is expected to positively impact inflation expectations and provide support for the stock market.
See More
Revvity (RVTY) Q1 2026 Earnings Transcript
See More
